I have no idea what is specifically driving the market in CST today.
However, you are basically right re the US. CSTs QuantiFEREON-TB GOLD is FDA approved in the US and the CDC guidelines for it's use are scheduled for release at the end of this month.
As for sales. They have commenced everywhere around the world already. In the US the CDC guidelines will accelerate sales in that market. In Japan, whilst sales have commenced, they will surge when the new TB control guidelines are released in April. Europe sales are already accelerating.
It's all good news.
I should imagine that slowly but surely, as each milestone is reached, more and more instos, fundies and brokers will start showing interest in the stock. Perhaps that has caused the current run. The problem that they have is that this stock is very tightly held by the Directors and investors who have a detailed understanding of the business - it is hard to shake significant shares loose.
CST Price at posting:
0.0¢ Sentiment: None Disclosure: Held
